CARLSBAD, Calif., Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings. .

2023年9月21日/PRNewswire/-Tyra-Biosciences，Inc.（纳斯达克股票代码：Tyra），一家临床阶段的生物技术公司，专注于开发针对成纤维细胞生长因子受体（FGFR）生物学，今天宣布，TYRA将在美国骨矿物质研究学会（ASBMR）和美国人类遗传学会（ASHG）2023年会上就TYRA-300进行软骨发育不全的口头报告。 .

ASBMR is taking place October 13-16, 2023, in Vancouver, BC, Canada and ASHG is taking place November 1-5, 2023, in Washington, DC.

ASBMR于2023年10月13日至16日在加拿大不列颠哥伦比亚省温哥华举行，ASHG于2023年11月1日至5日在华盛顿特区举行。

ASBMR presentation details:

ASBMR演示详情：

Title: 'TYRA-300 Demonstrates Significant Increases in Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal Dysplasia'Presentation Number: 1077Session: Oral Presentations: Skeletal Development and DiseasePresentation Date/Time: Sunday, October 15, 2023, 10:00 AMTYRA Presenter: Ronald Swanson, Ph.D., Chief Scientific Officer.

题目：'TYRA-300显示FGFR3相关骨骼发育不良小鼠模型的生长和骨长度显着增加'报告编号：1077会议：口头报告：骨骼发育和疾病报告日期/时间：2023年10月15日星期日，10:00 AMTYRA主持人：首席科学官Ronald Swanson博士。

ASHG presentation details:

ASHG演示细节：

Title: 'TYRA-300 Demonstrates Significant Increases in Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal Dysplasia'Session: Oral Presentations: Precision prescription: The therapeutic potential of ASOs and small molecules for genetic disordersPresentation Date/Time: Friday, November 3, 2023, 12:00 PMTYRA Presenter: Jacqueline H.

题目：'TYRA-300显示FGFR3相关骨骼发育不良小鼠模型中生长和骨长度显着增加'会议：口头报告：精确处方：ASO和小分子对遗传性疾病的治疗潜力表示日期/时间：周五，2023年11月3日，12:00 PMTYRA主持人：Jacqueline H。

Starrett, PhD, Associate Director, In Vivo Pharmacology.

Starrett博士，体内药理学副主任。

More information on the annual meetings can be found below:

有关年会的更多信息，请参阅下文：

ASBMR 2023 Annual Meeting - American Society for Bone and Mineral Research

ASBMR 2023年会-美国骨与矿物研究学会

ASHG 2023 Scientific Program and Schedule of Events - ASHG

ASHG 2023科学计划和活动时间表-ASHG

The presentation materials will be made available via the For Investors page on the Investor section of the TYRA website.

演示材料将通过TYRA网站投资者部分的投资者页面提供。

About TYRA-300

关于TYRA-300

TYRA-300 is the Company's lead precision medicine program stemming from its in-house SNÅP platform. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias including achondroplasia. TYRA-300 is being evaluated in a multi-center, open label Phase 1/2 clinical study, SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumors).

TYRA-300是该公司的领先精准医药计划，源于其内部的SNÅP平台。TYRA-300是目前正在开发的用于治疗癌症和骨骼发育不良（包括软骨发育不全）的研究性口服FGFR3选择性抑制剂。TYRA-300正在一项多中心，开放标签的1/2期临床研究SURF301（未经治疗和耐药的FGFR3+晚期实体瘤研究）中进行评估。

SURF301 (NCT05544552) was designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate the preliminary antitumor activity of TYRA-300. SURF301 is currently enrolling adults with advanced urothelial carcinoma and other solid tumors with FGFR3 gene alterations.

SURF301（NCT05544552）旨在确定TYRA-300的最佳和最大耐受剂量（MTD）和推荐的2期剂量（RP2D），以及评估TYRA-300的初步抗肿瘤活性。SURF301目前正在招募患有晚期尿路上皮癌和其他具有FGFR3基因改变的实体瘤的成人。

In skeletal dysplasias, TYRA-300 has demonstrated positive preclinical results and the Company expects to submit an IND for the initiation of a Phase 2 clinical study in pediatric achondroplasia in 2024..

在骨骼发育不良中，TYRA-300已显示出积极的临床前结果，该公司预计将于2024年提交IND，以启动小儿软骨发育不全的2期临床研究。。

About Tyra Biosciences

关于Tyra生物科学

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies.

Tyra Biosciences，Inc.（纳斯达克股票代码：Tyra）是一家临床阶段的生物技术公司，专注于开发针对FGFR生物学巨大机遇的下一代精密药物。该公司内部的精准医学平台SNÅP通过迭代分子SNÅPshots实现快速，精确的药物设计，有助于预测最有可能导致对现有疗法获得性耐药的遗传改变。

TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA. .

TYRA最初的重点是应用其加速的小分子药物发现引擎来开发靶向肿瘤学和基因定义条件下的治疗方法。TYRA总部位于加利福尼亚州卡尔斯巴德。

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

有关我们的科学，管道和人员的更多信息，请访问www.tyra.bio并与我们联系LinkedIn。

Contact:

联系方式：

Amy Conrad[email protected]

艾米康拉德[电子邮件保护]

SOURCE Tyra Biosciences

资料来源：Tyra生物科学